Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2693 in Non-cirrhotic NASH with Fibrosis and PNPLA3 rs738409 148M
2023-509704-14-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing AZD2693 with Placebo (2 arms). Primary endpoint: Resolution of NASH without worsening of liver fibrosis at Week 52. Started Apr 2023; status: completed.
02
Drugs
AZD2693
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2023-509704-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509704-14-00.